IN2014DN06781A - - Google Patents

Download PDF

Info

Publication number
IN2014DN06781A
IN2014DN06781A IN6781DEN2014A IN2014DN06781A IN 2014DN06781 A IN2014DN06781 A IN 2014DN06781A IN 6781DEN2014 A IN6781DEN2014 A IN 6781DEN2014A IN 2014DN06781 A IN2014DN06781 A IN 2014DN06781A
Authority
IN
India
Prior art keywords
salt
salts
cushing
aromatase
pyrrolo
Prior art date
Application number
Other languages
English (en)
Inventor
Paul Sutton
Eric Loeser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47604250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN06781(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014DN06781A publication Critical patent/IN2014DN06781A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN6781DEN2014 2012-01-17 2013-01-15 IN2014DN06781A (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261587280P 2012-01-17 2012-01-17
PCT/US2013/021521 WO2013109514A1 (en) 2012-01-17 2013-01-15 New forms and salts of a dihydropyrrolo[1,2-c]imidazolyl aldosterone synthase or aromatase inhibitor

Publications (1)

Publication Number Publication Date
IN2014DN06781A true IN2014DN06781A (cs) 2015-05-22

Family

ID=47604250

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6781DEN2014 IN2014DN06781A (cs) 2012-01-17 2013-01-15

Country Status (40)

Country Link
US (2) US9334276B2 (cs)
EP (1) EP2804863B1 (cs)
JP (1) JP5749410B2 (cs)
KR (2) KR20140093726A (cs)
CN (1) CN104039793B (cs)
AP (1) AP2014007762A0 (cs)
AR (1) AR089728A1 (cs)
AU (1) AU2013209952B2 (cs)
BR (1) BR112014017260A8 (cs)
CA (1) CA2863339C (cs)
CL (1) CL2014001863A1 (cs)
CO (1) CO7000775A2 (cs)
CR (1) CR20140345A (cs)
CU (1) CU20140086A7 (cs)
CY (1) CY1117914T1 (cs)
DK (1) DK2804863T3 (cs)
EA (1) EA026232B1 (cs)
ES (1) ES2564143T3 (cs)
GT (1) GT201400155A (cs)
HR (1) HRP20160178T1 (cs)
HU (1) HUE026984T2 (cs)
IL (1) IL233541B (cs)
IN (1) IN2014DN06781A (cs)
JO (1) JO3137B1 (cs)
MA (1) MA35858B1 (cs)
MX (1) MX2014008686A (cs)
NZ (1) NZ626277A (cs)
PE (1) PE20142358A1 (cs)
PH (1) PH12014501638A1 (cs)
PL (1) PL2804863T3 (cs)
RS (1) RS54589B1 (cs)
SG (1) SG11201404061YA (cs)
SI (1) SI2804863T1 (cs)
SM (1) SMT201600083B (cs)
TN (1) TN2014000256A1 (cs)
TW (1) TWI609869B (cs)
UA (1) UA114803C2 (cs)
UY (1) UY34576A (cs)
WO (1) WO2013109514A1 (cs)
ZA (1) ZA201404314B (cs)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2598708C2 (ru) * 2010-01-14 2016-09-27 Новартис Аг Применение агента, обладающего модифицирующими свойствами в отношении гормонов надпочечников
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
SG11201610227TA (en) * 2014-07-07 2017-01-27 Novartis Ag Pharmaceutical dosage forms
US10556869B2 (en) 2015-01-29 2020-02-11 Novartis Ag Process for the production of condensed imidazolo derivatives
US20160287565A1 (en) * 2015-04-06 2016-10-06 Millendo Therapeutics, Inc. Combination therapy for treating disorders associated with excess cortisol production
US10822332B2 (en) 2016-10-27 2020-11-03 Damian Pharma Ag Aldosterone synthase inhibitor
WO2018078049A1 (en) * 2016-10-27 2018-05-03 Damian Pharma Ag Aldosterone synthase inhibitor
BR112020022173A2 (pt) 2018-05-03 2021-02-02 Damian Pharma Ag r-fadrozol para uso no tratamento de aldostonerismo

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1315449A (en) * 1918-11-15 1919-09-09 Frank B Yingling Shaper-feed.
US4617307A (en) * 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US5066656A (en) 1989-11-01 1991-11-19 Janssen Pharmaceutica N.V. Pharmacologically active (6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1H-benzotriazole derivatives
MTP1076B (en) * 1990-01-12 1991-09-30 Ciba Geigy Ag Hemihydrate
DK0625155T3 (da) 1992-01-27 2001-11-12 Janssen Pharmaceutica Nv Pyrroloimidazolyl- og imidazopyridinyl-substituerede 1H-benzimidazolderivater som aromataseinhibitorer
ES2305520T3 (es) * 2002-11-18 2008-11-01 Novartis Ag Derivados de imidazo(1,5a)piridina y metodos para tratar enfermedades mediadas por aldosterona.
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
KR20090094374A (ko) 2006-12-18 2009-09-04 노파르티스 아게 1-치환된 이미다졸 유도체 및 알도스테론 신타제 억제제로서의 그의 용도
WO2011064376A1 (en) 2009-11-30 2011-06-03 Novartis Ag Imidazole derivatives as aldosterone synthase inhibitors
RU2598708C2 (ru) * 2010-01-14 2016-09-27 Новартис Аг Применение агента, обладающего модифицирующими свойствами в отношении гормонов надпочечников

Also Published As

Publication number Publication date
CL2014001863A1 (es) 2014-11-07
UA114803C2 (uk) 2017-08-10
TN2014000256A1 (en) 2015-09-30
MA35858B1 (fr) 2014-12-01
EA026232B1 (ru) 2017-03-31
JO3137B1 (ar) 2017-09-20
AP2014007762A0 (en) 2014-07-31
NZ626277A (en) 2015-10-30
JP2015503627A (ja) 2015-02-02
ES2564143T3 (es) 2016-03-18
IL233541B (en) 2018-12-31
ES2564143T8 (es) 2020-11-18
AU2013209952B2 (en) 2016-09-01
HRP20160178T1 (hr) 2016-03-25
CN104039793B (zh) 2017-05-10
JP5749410B2 (ja) 2015-07-15
HK1198536A1 (en) 2015-05-15
CA2863339C (en) 2021-03-23
TWI609869B (zh) 2018-01-01
EP2804863A1 (en) 2014-11-26
CY1117914T1 (el) 2017-05-17
US9334276B2 (en) 2016-05-10
US20140364470A1 (en) 2014-12-11
DK2804863T3 (en) 2016-03-07
SG11201404061YA (en) 2014-08-28
SI2804863T1 (sl) 2016-05-31
CU20140086A7 (es) 2014-12-26
PL2804863T3 (pl) 2016-06-30
AU2013209952A1 (en) 2014-07-24
US20160176883A1 (en) 2016-06-23
CR20140345A (es) 2014-09-09
IL233541A0 (en) 2014-08-31
AR089728A1 (es) 2014-09-10
PH12014501638B1 (en) 2014-10-13
PE20142358A1 (es) 2015-01-30
KR20140093726A (ko) 2014-07-28
HUE026984T2 (en) 2016-08-29
WO2013109514A1 (en) 2013-07-25
BR112014017260A8 (pt) 2017-07-04
EA201491374A1 (ru) 2014-12-30
PH12014501638A1 (en) 2014-10-13
MX2014008686A (es) 2014-08-27
KR20140141687A (ko) 2014-12-10
CO7000775A2 (es) 2014-07-21
EP2804863B1 (en) 2015-12-02
ZA201404314B (en) 2015-08-26
RS54589B1 (sr) 2016-08-31
TW201335161A (zh) 2013-09-01
UY34576A (es) 2013-09-02
CN104039793A (zh) 2014-09-10
CA2863339A1 (en) 2013-07-25
GT201400155A (es) 2017-09-28
BR112014017260A2 (pt) 2017-06-13
SMT201600083B (it) 2016-04-29

Similar Documents

Publication Publication Date Title
IN2014DN06781A (cs)
IL290905A (en) Crystal form of (s)–n-(5–)–2–(r))5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-a]pyrimidine-3-yl)-3 -Hydroxypyrrolidine-1-carboxamide hydrogen sulfate
IL235659A0 (en) History of 3, 4 - dihydro -2h - pyrido [1, 2 - a] pyrazine - 1,2,1] 6 converted diones used to treat (among others) Alzheimer's disease
PH12013500872A1 (en) Salt(s) of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
IN2014DN07384A (cs)
PL3808749T3 (pl) Pirazolo[1,5-a]pirymidyny użyteczne jako inhibitory kinazy atr do leczenia chorób nowotworowych
PH12015500988B1 (en) Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
GEP20156285B (en) Compounds and compositions as trk inhibitors
HRP20182007T1 (hr) Derivati 3-okso-2,3,5,8-tetrahidro-[1,2,4]triazolo[4,3-a]pirimidina za liječenje respiratornih bolesti
HK1216425A1 (zh) 基於2,3-二氢咪唑并[1,2-c]嘧啶-5(1h)-酮的脂蛋白相关磷脂酶a2(lp-pla2)抑制剂
MX2012002327A (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
TN2013000377A1 (en) Thieno [2, 3-d] pyrimidine derivatives and their use to treat arrhythmia
TN2013000483A1 (en) Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
MX384986B (es) Sal y formas polimorficas de (3r,4s)-l-((4-amino-5h-pirrolo[3,2-d]pirimidin-7-il)metil)-4(metiltiometil)pirodin-3-ol(mtdia).
TN2013000146A1 (en) Salt(s) of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof